US5422260A
(en)
*
|
1986-05-29 |
1995-06-06 |
Genetics Institute, Inc. -Legal Affairs |
Human factor VIII:c muteins
|
US5171844A
(en)
|
1987-06-12 |
1992-12-15 |
Gist-Brocades N.W. |
Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
SE465222C5
(sv)
*
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
CA2073859A1
(en)
*
|
1990-01-26 |
1991-07-27 |
Falko-Guenter Falkner |
Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process
|
FR2657884B1
(fr)
|
1990-02-05 |
1994-09-02 |
Tm Innovation |
Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
|
US5833982A
(en)
|
1991-02-28 |
1998-11-10 |
Zymogenetics, Inc. |
Modified factor VII
|
US5997864A
(en)
|
1995-06-07 |
1999-12-07 |
Novo Nordisk A/S |
Modified factor VII
|
US5661008A
(en)
*
|
1991-03-15 |
1997-08-26 |
Kabi Pharmacia Ab |
Recombinant human factor VIII derivatives
|
DE69229390T2
(de)
*
|
1991-08-26 |
1999-11-11 |
Immuno Ag, Wien |
Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
|
DK53792D0
(da)
*
|
1992-04-24 |
1992-04-24 |
Novo Nordisk As |
Fremgangsmaade til fremstilling af proteiner
|
WO1994011525A1
(en)
*
|
1992-11-17 |
1994-05-26 |
Novo Nordisk A/S |
Improved recombinant production of proteins having factor viii:c activity
|
SE504074C2
(sv)
*
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
DE4437544A1
(de)
*
|
1994-10-20 |
1996-04-25 |
Behringwerke Ag |
Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
|
US6200560B1
(en)
*
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
EP1038959A1
(de)
|
1999-03-17 |
2000-09-27 |
Aventis Behring Gesellschaft mit beschränkter Haftung |
Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
|
US20040023292A1
(en)
*
|
2001-10-19 |
2004-02-05 |
Mcswiggen James |
Method and reagent for the detection of proteins and peptides
|
EP1233064A1
(de)
|
2001-02-09 |
2002-08-21 |
Aventis Behring Gesellschaft mit beschränkter Haftung |
Modifizierte Faktor VIII cDNA und deren Verwendung bei der Produktion von Faktor VIII
|
EP1284290A1
(de)
*
|
2001-08-08 |
2003-02-19 |
Aventis Behring GmbH |
Erhöhung der Expression von Faktor VIII durch Insertion von spleissbaren Nukleotidsequenzen in Faktor VIII cDNA
|
EP1424344A1
(de)
*
|
2002-11-29 |
2004-06-02 |
Aventis Behring Gesellschaft mit beschränkter Haftung |
Modifizierte cDNA des Factors VIII und Derivate davon
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
DK2292780T3
(en)
|
2003-09-30 |
2017-12-04 |
Univ Pennsylvania |
Clades and sequences of adeno-associated virus (AAV), vectors containing them, and uses thereof
|
CA2579374A1
(en)
*
|
2004-09-07 |
2006-03-30 |
Archemix Corp. |
Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
|
US7566701B2
(en)
*
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
JP2008512097A
(ja)
*
|
2004-09-07 |
2008-04-24 |
アーケミックス コーポレイション |
アプタマー医薬品化学
|
EP1707634A1
(de)
|
2005-03-29 |
2006-10-04 |
Octapharma AG |
Verfahren zur Isolierung von rekombinant hergestellten Proteinen
|
WO2006110689A2
(en)
|
2005-04-07 |
2006-10-19 |
The Trustees Of The University Of Pennsylvania |
Method of increasing the function of an aav vector
|
EP1739179A1
(de)
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
US9441030B2
(en)
|
2007-02-23 |
2016-09-13 |
Sk Chemicals Co., Ltd. |
Process for producing and purifying factor VIII and its derivatives
|
US20090203766A1
(en)
*
|
2007-06-01 |
2009-08-13 |
Archemix Corp. |
vWF aptamer formulations and methods for use
|
CA2748314C
(en)
|
2009-02-03 |
2018-10-02 |
Amunix Operating Inc. |
Extended recombinant polypeptides and compositions comprising same
|
WO2011028229A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor ix compositions and methods of making and using same
|
CA2782424C
(en)
|
2009-12-06 |
2021-07-27 |
Biogen Idec Hemophilia Inc. |
Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
|
WO2011095604A1
(en)
|
2010-02-04 |
2011-08-11 |
Octapharma Biopharmaceuticals Gmbh |
Half-life prolongation of proteins
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
SG183929A1
(en)
|
2010-03-29 |
2012-10-30 |
Univ Pennsylvania |
Pharmacologically induced transgene ablation system
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
US20130216513A1
(en)
|
2010-07-09 |
2013-08-22 |
Biogen Idec Hemophilia Inc. |
Chimeric Clotting Factors
|
ES2724800T3
(es)
|
2011-02-17 |
2019-09-16 |
Univ Pennsylvania |
Composiciones y métodos para alterar la especificidad de tejido y mejorar la transferencia génica mediada por AAV9
|
US9486507B2
(en)
|
2011-06-10 |
2016-11-08 |
Biogen Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
WO2013009627A2
(en)
|
2011-07-08 |
2013-01-17 |
Biogen Idec Hemophilia Inc. |
Factor viii chimeric and hybrid polypeptides, and methods of use thereof
|
US10656167B2
(en)
|
2011-07-25 |
2020-05-19 |
Bioverativ Therapeutics Inc. |
Assays to monitor bleeding disorders
|
CA2850579A1
(en)
|
2011-10-18 |
2013-04-25 |
Carsten Horn |
Method for improving the stability of purified factor viii after reconstitution
|
PT2804623T
(pt)
|
2012-01-12 |
2019-11-18 |
Bioverativ Therapeutics Inc |
Polipéptidos quiméricos do fator viii e suas utilizações
|
ES2899848T3
(es)
|
2012-01-12 |
2022-03-15 |
Bioverativ Therapeutics Inc |
Reducción de la inmunogenicidad contra el factor VIII en individuos sometidos a una terapia con factor VIII
|
LT3564260T
(lt)
|
2012-02-15 |
2023-01-10 |
Bioverativ Therapeutics Inc. |
Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
|
CA2864126A1
(en)
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
JP2015525222A
(ja)
|
2012-06-08 |
2015-09-03 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
キメラ性凝固因子
|
EP4079316A1
(de)
|
2012-06-08 |
2022-10-26 |
Bioverativ Therapeutics Inc. |
Prokoagulatorische verbindungen
|
EP3404105A1
(de)
|
2012-07-06 |
2018-11-21 |
Bioverativ Therapeutics Inc. |
Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
|
BR112015000267B1
(pt)
|
2012-07-11 |
2023-01-24 |
Bioverativ Therapeutics Inc. |
Proteínas quiméricas, e composição farmacêutica
|
EP2877202A4
(de)
|
2012-07-25 |
2016-06-01 |
Biogen Ma Inc |
Blutfaktorüberwachungstest und verwendungen davon
|
EP2908847B1
(de)
|
2012-10-18 |
2022-03-30 |
Bioverativ Therapeutics Inc. |
Verfahren zur verwendung einer festgelegten dosis eines blutgerinnungsfaktors
|
EP3943102A1
(de)
|
2012-10-30 |
2022-01-26 |
Bioverativ Therapeutics Inc. |
Verfahren zur verwendung von fviii-polypeptid
|
FI2956477T4
(fi)
|
2013-02-15 |
2024-04-24 |
Bioverativ Therapeutics Inc |
Optimoitu tekijä viii:n geeni
|
SG11201505926VA
(en)
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
UY35462A
(es)
|
2013-03-15 |
2014-10-31 |
Biogen Idec Inc |
Formulación de un polipéptido del factor viii.
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
NZ713904A
(en)
|
2013-06-28 |
2022-02-25 |
Bioverativ Therapeutics Inc |
Thrombin cleavable linker with xten and its uses thereof
|
EP3875106A1
(de)
|
2013-08-08 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
Reinigung von chimären fviii-molekülen
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子viii-xten融合物及其用途
|
EP3065769A4
(de)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Prokoagulatorische fusionsverbindung
|
WO2015085276A1
(en)
|
2013-12-06 |
2015-06-11 |
Biogen Idec Ma Inc. |
Population pharmacokinetics tools and uses thereof
|
CN116621991A
(zh)
|
2014-01-10 |
2023-08-22 |
比奥贝拉蒂治疗公司 |
因子viii嵌合蛋白及其用途
|
WO2015107222A1
(en)
|
2014-01-20 |
2015-07-23 |
Octapharma Ag |
A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
|
EP3102589A1
(de)
|
2014-02-04 |
2016-12-14 |
Biogen MA Inc. |
Verwendung von kationenaustauscherchromatographie im durchflussmodus zur anreicherung von posttranslationalen modifikationen
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
WO2016168728A2
(en)
|
2015-04-16 |
2016-10-20 |
Emory University |
Recombinant promoters and vectors for protein expression in liver and use thereof
|
EA201890423A1
(ru)
|
2015-08-03 |
2018-07-31 |
Биовератив Терапьютикс Инк. |
Слитые белки фактора ix, способы их получения и применения
|
JP6695426B2
(ja)
|
2015-11-13 |
2020-05-20 |
バクスアルタ インコーポレイテッド |
組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター
|
CN108884145B
(zh)
|
2015-11-13 |
2023-08-22 |
武田药品工业株式会社 |
用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
|
PL3411478T3
(pl)
|
2016-02-01 |
2022-10-03 |
Bioverativ Therapeutics Inc. |
Geny zoptymalizowanego czynnika VIII
|
WO2017222337A1
(ko)
|
2016-06-24 |
2017-12-28 |
재단법인 목암생명과학연구소 |
Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
|
EP3548066A1
(de)
|
2016-12-02 |
2019-10-09 |
Bioverativ Therapeutics Inc. |
Verfahren zur behandlung von hämophile arthropathie unter verwendung chimärer gerinnungsfaktoren
|
MX2019006446A
(es)
|
2016-12-02 |
2019-12-11 |
Bioverativ Therapeutics Inc |
Métodos para inducir tolerancia inmunológica a factores de coagulación.
|
SG11202000764RA
(en)
|
2017-08-09 |
2020-02-27 |
Bioverativ Therapeutics Inc |
Nucleic acid molecules and uses thereof
|
AU2018366110B2
(en)
|
2017-11-07 |
2024-08-08 |
Rani Therapeutics, Llc |
Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
|
US20210038744A1
(en)
|
2018-02-01 |
2021-02-11 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor viii
|
IL277713B2
(en)
|
2018-04-04 |
2024-09-01 |
Sigilon Therapeutics Inc |
Implantable particles and related methods
|
SG11202010767SA
(en)
|
2018-05-18 |
2020-11-27 |
Bioverativ Therapeutics Inc |
Methods of treating hemophilia a
|
TW202006141A
(zh)
|
2018-07-16 |
2020-02-01 |
美商巴克斯歐塔公司 |
使用編碼具有增加表現的重組fviii變異體之病毒載體的a型血友病之基因療法
|
BR112021002017A2
(pt)
|
2018-08-09 |
2021-05-11 |
Bioverativ Therapeutics Inc. |
moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
EA202191977A1
(ru)
|
2019-01-16 |
2021-12-15 |
Баксалта Инкорпорейтед |
Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии а
|
BR112021025426A2
(pt)
|
2019-06-19 |
2022-06-21 |
Bioverativ Therapeutics Inc |
Fator recombinante viii-fc para tratamento de hemofilia e baixa densidade mineral óssea
|
US20230023826A1
(en)
|
2019-12-12 |
2023-01-26 |
Takeda Pharmaceutical Company Limited |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
JP2023537070A
(ja)
|
2020-08-07 |
2023-08-30 |
アミカス セラピューティックス インコーポレイテッド |
小胞を標的とするタンパク質及びその使用
|
EP4355768A1
(de)
|
2021-06-14 |
2024-04-24 |
Takeda Pharmaceutical Company Limited |
Gentherapie von hämophilie a unter verwendung von für rekombinante fviii-varianten codierenden viralen vektoren mit erhöhter expression
|
WO2023028456A1
(en)
|
2021-08-23 |
2023-03-02 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
WO2023056331A1
(en)
|
2021-09-30 |
2023-04-06 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
WO2024081309A1
(en)
|
2022-10-11 |
2024-04-18 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|